Caspase 6 (Casp6) has been implicated in several neurodegenerative conditions, including Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease. Casp6 activation has been observed during all stages of Alzheimer’s disease making it an attractive therapeutic target for neurological indications. The current invention identifies a family of covalent small molecules that selectively bind Casp6 over other caspases.
In 2018, the global market for neurodegenerative disease drugs was valued at over US$35 billion, and projected to exceed US$62 billion by 2026. While a known target in neurodegenerative disease, historically, caspases in general and Casp6 in particular have proven difficult to drug, with previously available inhibitors showing little specificity between the different caspase family members. UCSF investigators have identified small molecule covalent inhibitors that demonstrate good selectivity for Casp6 over other family members. These compounds can be developed as:
To develop & commercialize the technology for all clinical applications.
Under CDA / NDA